CD52 and graft versus host disease: Using proprietary TALEN gene editing, the TCR alpha constant gene is disrupted in ALLO-715 to lower the risk of graft-versus-host disease (GVHD) while the CD52 gene is disrupted to allow for lymphodepletion of native T cells with an anti-CD52 antibody similar to alemtuzumab (116).